Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pluvicto
Biotech
Novartis drops ph. 2-stage radioligand therapy over poor data
Novartis CEO Vas Narasimhan told Fierce that the company’s commitment to radioligand therapies “remains completely unchanged.”
James Waldron
Jul 21, 2026 8:18am
ASCO: Telix tees up pivotal test for Pluvicto challenger
Jun 1, 2026 4:12pm
Fierce Pharma
Novartis pledges nearly $480M to bolster China production, R&D
Mar 23, 2026 10:35am
ESMO: Lantheus' radiotherapy readout not enough to best Pluvicto
Sep 16, 2024 8:55am
Novartis entrenches into radiopharma with $1B Mariana buy
May 2, 2024 7:00am
How Novartis is disrupting Lilly's $1.4B radiotherapy plan
Dec 5, 2023 11:21am
